The activation of telomere maintenance mechanisms (TMMs) by multiple genetic alterations, such as TERT rearrangements, MYCN amplification, and ATRX mutations, is emphasized in relapsed neuroblastoma and has a markedly poor prognosis, especially when associated with MAPK or p53 pathway mutations (8) (Table 1). The gene discussed is MYCN; the disease is neuroblastoma.